Benitec Biopharma (BNTC) Set to Post Quarterly Earnings on Friday

Benitec Biopharma (NASDAQ:BNTC) is anticipated to announce its Q1 2027 results before the market opens on Friday, November 13th. Analysts expect the company to post earnings of ($0.2686) per share for the quarter. Interested persons may visit the company’s upcoming Q1 2027 earnings summary page for the latest details on the call scheduled for Friday, November 20, 2026 at 9:30 AM ET.

Benitec Biopharma (NASDAQ:BNTC) last posted its quarterly earnings results on Monday, September 14th. The biotechnology company reported ($0.26) EPS for the quarter, meeting the consensus estimate of ($0.26). On average, analysts expect Benitec Biopharma to post ($1.35) EPS for the current fiscal year and ($1.55) EPS for the next fiscal year.

Benitec Biopharma Stock Up 2.0%

Shares of BNTC stock opened at $9.47 on Thursday. The stock has a market cap of $330.41 million, a price-to-earnings ratio of -9.66 and a beta of 0.26. Benitec Biopharma has a fifty-two week low of $7.89 and a fifty-two week high of $14.39. The firm’s 50 day moving average price is $9.82 and its two-hundred day moving average price is $11.42.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on BNTC shares. Wall Street Zen downgraded shares of Benitec Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, September 19th. Citigroup restated a “market outperform” rating on shares of Benitec Biopharma in a report on Tuesday, October 6th. HC Wainwright reaffirmed a “buy” rating on shares of Benitec Biopharma in a research report on Monday, November 2nd. Royal Bank Of Canada upgraded Benitec Biopharma to an “outperform” rating in a report on Tuesday, September 15th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Benitec Biopharma in a report on Thursday, October 15th. Seven equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Benitec Biopharma presently has an average rating of “Moderate Buy” and an average target price of $22.00.

About Benitec Biopharma

Benitec Biopharma is a clinical-stage biotechnology company developing genetic medicines for serious diseases. Its approach uses DNA-directed RNA interference (ddRNAi), a technique designed to reduce the production of disease-causing proteins by directing cells to silence specific genes. The company’s lead investigational candidate, BB-301, is being developed for oculopharyngeal muscular dystrophy (OPMD), a rare inherited disorder that can cause progressive muscle weakness and difficulty swallowing.